Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial is a study to test a new treatment for a specific type of stroke called intracerebral hemorrhage (ICH), which is bleeding in the brain. The study checks if rFVIIa, a special protein, stops bleeding better than regular treatments. Participants must be treated quickly, within 2 hours of stroke symptoms, and are randomly given either rFVIIa or a placebo (a harmless substance that looks the same). They also receive the best standard care for stroke.
In this trial, people aged 18-80 with a certain amount of brain bleeding can join. They are followed up for 6 months to see how well they recover, using the Modified Rankin Score (mRS), a tool to measure stroke recovery. The study will take place in several countries, including the US and the UK.
Key Points:
- Participants are treated within 2 hours of a stroke.
- Randomly assigned to receive either rFVIIa or a placebo.
- Follow-up visits at 30 days, 90 days, and 180 days after treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand